The predictive role of circulating telomerase and vitamin D for long-term survival in patients undergoing coronary artery bypass grafting surgery (CABG).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
06
2020
accepted:
27
07
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
9
10
2020
Statut:
epublish
Résumé
Cardiovascular disease (CVD) is the leading cause of mortality all over the globe. Inflammation is believed to play a pivotal role in the pathophysiology of CVD. While there are studies on the interrelationship of telomerase and vitamin D and their involvement in CVD, their independent contributions to long-term outcomes in patients with CVD are not well-defined. This study aimed to investigate the association of both telomerase and vitamin D concentrations with 10-year survival among candidates of coronary artery bypass grafting (CABG) surgery. Participants were 404 patients from Tehran Heart Center-Coronary Outcome Measurement (THC-COM) cohort who were recruited from CABG surgery candidates in 2006. In addition to demographic and clinical data including risk factors for coronary artery disease, laboratory parameters such as markers of inflammation as well as baseline serum 25-hydroxy vitamin D [25(OH)D] and telomerase concentrations were measured. Cardiac function indexes alongside outcome measures such as mortality and survival days were recorded for every patient up to 10 years after CABG. Cox-proportional hazard model was used to study the association between all-cause mortality and research parameters. The mean serum telomerase enzyme level was 24.92 ±21.4 nmol/L and the mean serum 25(OH)D was 27.27±10.3 ng/mL. 10-year mortality was reported in 64 (15.8%) patients. 25(OH)D was categorized into three groups (<20, 20-30, and >30) and the cut-point for telomerase was set at 25.0 nmol/L. In Cox regression analysis, higher levels of telomerase (>25 nmol/L) were significantly associated with longer survival (p = 0.041), whereas 25(OH)D concentrations were not associated with survival time. Further analysis showed that telomerase concentrations significantly predicted survival only in the presence of insufficient levels of 25(OH)D (20-30 ng/mL) (p = 0.037). Telomerase can be regarded as a potential predictor of long-term outcomes in patients who underwent CABG. However, the association of telomerase with the mortality may be modified by vitamin D concentrations.
Sections du résumé
BACKGROUNDS
Cardiovascular disease (CVD) is the leading cause of mortality all over the globe. Inflammation is believed to play a pivotal role in the pathophysiology of CVD. While there are studies on the interrelationship of telomerase and vitamin D and their involvement in CVD, their independent contributions to long-term outcomes in patients with CVD are not well-defined. This study aimed to investigate the association of both telomerase and vitamin D concentrations with 10-year survival among candidates of coronary artery bypass grafting (CABG) surgery.
METHODS
Participants were 404 patients from Tehran Heart Center-Coronary Outcome Measurement (THC-COM) cohort who were recruited from CABG surgery candidates in 2006. In addition to demographic and clinical data including risk factors for coronary artery disease, laboratory parameters such as markers of inflammation as well as baseline serum 25-hydroxy vitamin D [25(OH)D] and telomerase concentrations were measured. Cardiac function indexes alongside outcome measures such as mortality and survival days were recorded for every patient up to 10 years after CABG. Cox-proportional hazard model was used to study the association between all-cause mortality and research parameters.
RESULTS
The mean serum telomerase enzyme level was 24.92 ±21.4 nmol/L and the mean serum 25(OH)D was 27.27±10.3 ng/mL. 10-year mortality was reported in 64 (15.8%) patients. 25(OH)D was categorized into three groups (<20, 20-30, and >30) and the cut-point for telomerase was set at 25.0 nmol/L. In Cox regression analysis, higher levels of telomerase (>25 nmol/L) were significantly associated with longer survival (p = 0.041), whereas 25(OH)D concentrations were not associated with survival time. Further analysis showed that telomerase concentrations significantly predicted survival only in the presence of insufficient levels of 25(OH)D (20-30 ng/mL) (p = 0.037).
CONCLUSIONS
Telomerase can be regarded as a potential predictor of long-term outcomes in patients who underwent CABG. However, the association of telomerase with the mortality may be modified by vitamin D concentrations.
Identifiants
pubmed: 32790742
doi: 10.1371/journal.pone.0237477
pii: PONE-D-20-17025
pmc: PMC7425905
doi:
Substances chimiques
Biomarkers
0
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237477Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Br J Nutr. 2009 Jan;101(2):278-84
pubmed: 18430263
Int J Obes (Lond). 2012 Jun;36(6):805-9
pubmed: 21986705
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
BMC Cardiovasc Disord. 2017 May 8;17(1):114
pubmed: 28482801
Rev Endocr Metab Disord. 2019 Sep;20(3):273-282
pubmed: 31654261
N Engl J Med. 2019 Jan 3;380(1):33-44
pubmed: 30415629
Am J Clin Nutr. 2007 Nov;86(5):1420-5
pubmed: 17991655
BMJ. 2014 Jul 08;349:g4227
pubmed: 25006006
Am J Epidemiol. 2013 Jun 15;177(12):1411-7
pubmed: 23660800
Horm Metab Res. 2016 Apr;48(4):269-74
pubmed: 26466019
Lancet. 2007 Jan 13;369(9556):107-14
pubmed: 17223473
Brain Behav Immun. 2016 Nov;58:248-253
pubmed: 27470228
J Clin Endocrinol Metab. 2011 Jul;96(7):1931-42
pubmed: 21677037
Int J Cardiol. 2016 Nov 15;223:962-966
pubmed: 27589046
Aging (Albany NY). 2008 Dec 04;1(1):81-8
pubmed: 20195384
Genes (Basel). 2016 Sep 01;7(9):
pubmed: 27598203
World J Cardiol. 2016 Nov 26;8(11):676-683
pubmed: 27957254
Biometrics. 1983 Jun;39(2):499-503
pubmed: 6354290
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3723-8
pubmed: 10097104
Nature. 2011 Jan 6;469(7328):102-6
pubmed: 21113150
Circ Cardiovasc Genet. 2015 Feb;8(1):82-90
pubmed: 25406241
Ann Intern Med. 2010 Mar 2;152(5):315-23
pubmed: 20194238
Clin Lab Med. 2000 Sep;20(3):569-90
pubmed: 10986622
Iran J Public Health. 2017 Apr;46(4):506-516
pubmed: 28540267
Circulation. 2011 Jul 19;124(3):314-23
pubmed: 21730306
Eat Weight Disord. 2020 Feb 13;:
pubmed: 32056109
Curr Vasc Pharmacol. 2014;12(5):726-34
pubmed: 24350925
Am J Epidemiol. 2007 Jan 1;165(1):14-21
pubmed: 17043079
Autoimmun Rev. 2013 Aug;12(10):976-89
pubmed: 23542507
Int Cardiovasc Res J. 2013 Dec;7(4):124-9
pubmed: 24757636
Ann Card Anaesth. 2015 Jul-Sep;18(3):293-8
pubmed: 26139731
J Am Coll Cardiol. 2018 Jun 5;71(22):2570-2584
pubmed: 29852980
Biosci Rep. 2019 Oct 30;39(10):
pubmed: 31647542
Eur J Endocrinol. 2019 Apr;180(4):P23-P54
pubmed: 30721133
Am J Clin Nutr. 2017 Apr;105(4):810-819
pubmed: 28251933
J Med Biochem. 2017 Oct 28;36(4):349-357
pubmed: 30581332
Lancet Oncol. 2008 Nov;9(11):1048-57
pubmed: 18799354
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):819-29
pubmed: 23149428
Clin Lab. 2018 Apr 1;64(4):483-490
pubmed: 29739077
BMC Med Genet. 2015 Jul 23;16:52
pubmed: 26201603
Nutrients. 2019 Oct 06;11(10):
pubmed: 31590434
FASEB J. 2012 Dec;26(12):4832-40
pubmed: 22919071